Listed

Cumberland Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 6, 2013 and accepted by EDGAR at Nov 6, 2013, 17:09 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$6.5mus-gaap:SalesRevenueNet
Revenue9 months2013-01-01 to 2013-09-30$23.9mus-gaap:SalesRevenueNet
Cost of revenue3 months2013-07-01 to 2013-09-30$1.0mus-gaap:CostOfGoodsSold
Cost of revenue9 months2013-01-01 to 2013-09-30$3.3mus-gaap:CostOfGoodsSold
Research and development3 months2013-07-01 to 2013-09-30$1.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2013-01-01 to 2013-09-30$4.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-07-01 to 2013-09-30−$1.5mus-gaap:OperatingIncomeLoss
Operating income9 months2013-01-01 to 2013-09-30−$1.3mus-gaap:OperatingIncomeLoss
Interest expense3 months2013-07-01 to 2013-09-30$24.3kus-gaap:InterestExpense
Interest expense9 months2013-01-01 to 2013-09-30$62.7kus-gaap:InterestExpense
Income tax3 months2013-07-01 to 2013-09-30−$686.2kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2013-01-01 to 2013-09-30−$590.3kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-07-01 to 2013-09-30−$819.9kus-gaap:NetIncomeLoss
Net income9 months2013-01-01 to 2013-09-30−$604.3kus-gaap:NetIncomeLoss
Diluted EPS3 months2013-07-01 to 2013-09-30−$0.04us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2013-01-01 to 2013-09-30−$0.03us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-07-01 to 2013-09-30−$0.04us-gaap:EarningsPerShareBasic
Basic EPS9 months2013-01-01 to 2013-09-30−$0.03us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2013-07-01 to 2013-09-3018,233,407 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2013-01-01 to 2013-09-3018,420,465 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2013-01-01 to 2013-09-30$938.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2013-01-01 to 2013-09-30$92.4kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2013-01-01 to 2013-09-30$3.9mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2013-09-30$46.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$78.3mus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$91.9mus-gaap:Assets
Current liabilitiesAt period end2013-09-30$5.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-09-30$11.0mus-gaap:Liabilities
Shareholders' equityAt period end2013-09-30$81.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001087294-13-000017. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.